Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27703209 | 0.95 | HRH3 (0.38) | HRH3PHGDHMGLLSLC18A3OPRM1 | |
| SCHEMBL4701914 | 0.90 | GRIN2B (0.35) | HRH3GRIN2B | |
| SCHEMBL2123464 | 0.86 | DPP4 (0.38) | HRH3PHGDHMGLLSLC18A3OPRM1 | |
| SCHEMBL26025505 | 0.78 | HRH3 (0.47) | HRH3PHGDHMGLLSLC18A3OPRM1 | |
| SCHEMBL5868081 | 0.76 | NCF1 (0.50) | HRH3PHGDHMGLLSLC18A3OPRM1 | |
| SCHEMBL13181314 | 0.76 | OPRL1 (0.42) | HRH3PHGDHMGLLSLC18A3OPRM1 | |
| SCHEMBL772294 | 0.76 | MEN1 (0.35) | PHGDHMGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL772540 | 0.76 | MEN1 (0.35) | PHGDHMGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL772419 | 0.76 | MEN1 (0.35) | PHGDHMGLLMEN1KMT2AALDH1A1 | |
| SCHEMBL24146229 | 0.74 | OPRL1 (0.45) | HRH3PHGDHMGLLSLC18A3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102153562-B | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | claimed |
| CN-102153562-A | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-08-17 | — | — | CN | claimed |
| US-20090176779-A1 | PYRAZOLO[4,3-D]THIAZOLE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | claimed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | claimed |
| CN-102153562-B | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2015-05-13 | — | — | CN | disclosed |
| CN-103271906-A | Use of spiro-oxindole compounds as therapeutic agents | XENON PHARMACEUTICALS INC | 2013-09-04 | — | — | CN | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| CN-102153562-A | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-08-17 | — | — | CN | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| CN-101631546-A | Use of spiro-indolone compounds as therapeutic agents | XENON PHARMACEUTICALS INC | 2010-01-20 | — | — | CN | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | HRH3 4130/4885PHGDH 2971/4885MGLL 3945/4885 |
| US-20090176779-A1 | PYRAZOLO[4,3-D]THIAZOLE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATION THEREOF | TP53, PDK1, RB1 | HRH3 1953/4885PHGDH 1691/4885MGLL 4823/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HRH3 4130/4885PHGDH 2971/4885MGLL 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.